TytoCare

Company Overview

Snapshot

Founded in June 2012 by Dedi Gilad and Ofer Tzadik, TytoCare operates with 201–500 employees. The company has raised over $203.6 million across 8 funding rounds from 20 investors, with Insight Partners being a notable lead investor. In April 2026, TytoCare secured FDA De Novo authorization for its AI-powered eardrum analysis, marking a significant advancement in remote diagnostics.

Business overview

TytoCare is a virtual healthcare company that delivers remote primary care through its Home Smart Clinic. This solution combines an FDA-cleared, easy-to-use device with AI-powered guidance and diagnostic support, enabling families to conduct remote physical exams that replicate in-clinic experiences. The company's offerings also include the Pro Smart Clinic for professional settings such as rural clinics, schools, and workplaces. TytoCare serves over 220 major health systems and health plans across the U.S., Europe, Asia, Latin America, and the Middle East, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices.

Strategic signal

In April 2026, TytoCare received FDA De Novo authorization for its AI-powered eardrum analysis. This milestone is crucial as it validates the company's advanced diagnostic capabilities and expands the scope of conditions that can be accurately assessed remotely. For investors, this signals strong regulatory progress and a deepening competitive moat in the virtual care market, enhancing TytoCare's ability to deliver high-quality, accessible primary care from home.

Company Intelligence Q&A

What was a significant regulatory achievement for TytoCare in April 2026?

In April 2026, TytoCare secured FDA De Novo authorization for its AI-powered eardrum analysis, marking a significant advancement in remote diagnostic capabilities.

What strategic partnership did TytoCare announce in November 2025?

In November 2025, TytoCare announced an integration with Teladoc Health to augment virtual primary and urgent care. This collaboration will incorporate TytoCare's FDA-cleared home diagnostic technology into Teladoc's Primary360 and 24/7 Care programs, enabling remote comprehensive physical exams.

How was TytoCare's AI Respiratory Suite recognized in October 2025?

In October 2025, TytoCare's AI Respiratory Suite was recognized on TIME's Best Inventions of 2025 list. This acknowledgment followed the company's achievement of being the first to receive FDA clearance for AI-based detection of major abnormal lung sounds.

What organizational changes did TytoCare undergo in July 2025?

In July 2025, TytoCare underwent a restructuring process, which included laying off 35 employees in Israel and the U.S. Additionally, CEO Dedi Gilad transitioned to chairman, with COO Ofer Tzadik taking over daily operations, as the company aimed to streamline operations and focus on AI-driven diagnostics.